AlphaCore Capital LLC Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

AlphaCore Capital LLC boosted its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 287.6% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 5,411 shares of the company’s stock after acquiring an additional 4,015 shares during the quarter. Johnson & Johnson accounts for about 0.4% of AlphaCore Capital LLC’s portfolio, making the stock its 26th biggest holding. AlphaCore Capital LLC’s holdings in Johnson & Johnson were worth $959,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Magnolia Capital Management Ltd. boosted its position in Johnson & Johnson by 0.5% during the 1st quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock worth $1,978,000 after acquiring an additional 55 shares during the period. Howard Financial Services LTD. boosted its position in Johnson & Johnson by 2.1% during the 1st quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock worth $489,000 after acquiring an additional 57 shares during the period. American Financial Advisors LLC boosted its position in Johnson & Johnson by 2.1% during the 1st quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock worth $481,000 after acquiring an additional 57 shares during the period. Capital Investment Counsel Inc boosted its position in Johnson & Johnson by 0.8% during the 4th quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock worth $1,334,000 after acquiring an additional 59 shares during the period. Finally, Kwmg LLC boosted its position in Johnson & Johnson by 2.6% during the 1st quarter. Kwmg LLC now owns 2,354 shares of the company’s stock worth $417,000 after acquiring an additional 59 shares during the period. Institutional investors and hedge funds own 68.78% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research reports. UBS Group dropped their price objective on Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. SVB Leerink dropped their price objective on Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 13th. Daiwa Capital Markets initiated coverage on Johnson & Johnson in a research note on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Finally, Citigroup dropped their price objective on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $189.89.

Insider Activity

In other news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Down 0.4 %

Shares of Johnson & Johnson stock opened at $171.11 on Friday. The stock’s fifty day moving average is $175.21 and its 200-day moving average is $174.55. The firm has a market capitalization of $449.88 billion, a PE ratio of 24.91, a price-to-earnings-growth ratio of 3.32 and a beta of 0.59. The company has a quick ratio of 1.14, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The business had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. During the same quarter in the previous year, the company posted $2.48 earnings per share. Johnson & Johnson’s revenue for the quarter was up 3.0% compared to the same quarter last year. Equities analysts anticipate that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be issued a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.64%. Johnson & Johnson’s dividend payout ratio is 65.79%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.